Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNEXA-4
NL-OMON45055Phase 3Active, not recruiting
- Sponsor
- Portola Pharmaceuticals
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of andexanet alfa in Not applicable and anticoagulant-associated bleeding, sponsored by Portola Pharmaceuticals. Primary endpoints: Percent change in anti-factor Xa activity from baseline to nadir and Effective hemostasis. Started Jul 2016; status: active, not recruiting.
02
Drugs
andexanet alfa
03
Conditions
Not applicableanticoagulant-associated bleeding
Beyond the preview
Go deeper on NL-OMON45055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45055.